Jim Simons
RYTM icon

Jim Simons’s Rhythm Pharmaceuticals RYTM Stock Holding History

Jim Simons’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$22.4M Sell
258,011
-83,182
-24% -$8.09M 0.04% 606
2025
Q4 		$36.5M Sell
341,193
-205,400
-38% -$21.8M 0.06% 385
2025
Q3 		$55.2M Buy
546,593
+231,700
+74% +$21.5M 0.07% 320
2025
Q2 		$19.9M Buy
314,893
+300,781
+2,131% +$18.4M 0.03% 719
2025
Q1 		$748K Buy
+14,112
New +$783K ﹤0.01% 2569
2022
Q2 		– Sell
-23,100
Closed -$266K – 4521
2022
Q1 		$266K Buy
+23,100
New +$203K ﹤0.01% 3526
2021
Q3 		– Sell
-52,200
Closed -$1.02M – 3791
2021
Q2 		$1.02M Buy
52,200
+3,200
+7% +$66.4K ﹤0.01% 2654
2021
Q1 		$1.04M Buy
49,000
+39,000
+390% +$1.13M ﹤0.01% 2595
2020
Q4 		$297K Sell
10,000
-187,000
-95% -$4.75M ﹤0.01% 3038
2020
Q3 		$4.27M Sell
197,000
-38,900
-16% -$892K ﹤0.01% 1663
2020
Q2 		$5.26M Buy
235,900
+141,200
+149% +$2.75M ﹤0.01% 1619
2020
Q1 		$1.44M Buy
94,700
+49,053
+107% +$878K ﹤0.01% 2232
2019
Q4 		$1.05M Buy
45,647
+34,947
+327% +$776K ﹤0.01% 2610
2019
Q3 		$231K Buy
+10,700
New +$230K ﹤0.01% 3106

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Jim Simons's RYTM Position: Q1 2026 in Review

Jim Simons reduced its Rhythm Pharmaceuticals (RYTM) stake by 24% in Q1 2026, selling an estimated $8.09M and leaving 258,011 shares worth $22.4M. The position accounts for 0.04% of the portfolio, ranked #606.

Jim Simons first reported a position in RYTM in Q3 2019 and has held it in 14 quarters since. The position peaked at $55.2M in Q3 2025. 285 funds tracked by Wall St. Rank hold RYTM as of Q1 2026.

  • Jim Simons held 258,011 shares of Rhythm Pharmaceuticals worth $22.4M as of Q1 2026.
  • Jim Simons sold 83,182 Rhythm Pharmaceuticals shares in Q1 2026, an estimated $8.09M.
  • Rhythm Pharmaceuticals made up 0.04% of Jim Simons's portfolio in Q1 2026, its #606 holding.
  • Jim Simons first reported a position in Rhythm Pharmaceuticals in Q3 2019 and has held it in 14 quarters since.
  • Jim Simons's Rhythm Pharmaceuticals position peaked at $55.2M in Q3 2025.
  • 285 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q1 2026.

Based on Renaissance Technologies's 13F filing for Q1 2026, filed 14 May 2026.